
BioNTech SE American Depositary Share
BNTX
BNTX: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.
moreShow BNTX Financials
Recent trades of BNTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BNTX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Rna for treatment of autoimmune diseases Jul. 18, 2023
-
Patent Title: Particles comprising a shell with rna May. 30, 2023
-
Patent Title: Coronavirus vaccine Jan. 10, 2023
-
Patent Title: Individualized vaccines for cancer Nov. 22, 2022
-
Patent Title: 3′-utr sequences for stabilization of rna Nov. 08, 2022
-
Patent Title: Methods and compositions for stimulating immune response Oct. 18, 2022
-
Patent Title: Preparation and storage of liposomal rna formulations suitable for therapy Jul. 26, 2022
-
Patent Title: Formulation for administration of rna May. 03, 2022
-
Patent Title: Recombinant vaccines and use thereof Apr. 12, 2022
-
Patent Title: Predicting immunogenicity of t cell epitopes Jan. 11, 2022
-
Patent Title: Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof Jun. 29, 2021
-
Patent Title: Cytotoxic immunostimulating particles and uses thereof Apr. 20, 2021
-
Patent Title: Agonistic tumor necrosis factor (tnf) receptor binding agents Feb. 23, 2021
-
Patent Title: Particles comprising protamine and rna in combination with endosome destabilizing agents Aug. 04, 2020
-
Patent Title: Agents for treatment of claudin expressing cancer diseases Jul. 21, 2020
-
Patent Title: Hydrogen water generator May. 26, 2020
-
Patent Title: Methods of inducing t cell activation by administering an antibody comprising cd40 and 4-1bb (cd137) binding domains Oct. 29, 2019
-
Patent Title: Compositions and methods for diagnosis and treatment of cancer Aug. 06, 2019
-
Patent Title: Identification of surface-associated antigens for tumor diagnosis and therapy May. 28, 2019
-
Patent Title: Identification of tumor-associated markers for diagnosis and therapy Apr. 09, 2019
-
Patent Title: Tumor antigens for determining cancer therapy Jan. 29, 2019
-
Patent Title: Particles comprising single stranded rna and double stranded rna for immunomodulation Jan. 08, 2019
-
Patent Title: Modification of rna, producing an increased transcript stability and translation efficiency Oct. 23, 2018
-
Patent Title: Agents for treatment of claudin expressing cancer diseases Oct. 09, 2018
-
Patent Title: Site-specific antibody-mediated activation of proapoptotic cytokines: amaize (antibody-mediated apoptosis inducing cytokines) Apr. 17, 2018
-
Patent Title: Identification of tumor-associated cell surface antigens for diagnosis and therapy Mar. 06, 2018
-
Patent Title: Homo- and heterodimeric smac mimetic compounds as apoptosis inducers Aug. 15, 2017
-
Patent Title: Genetic products differentially expressed in tumors and use thereof May. 02, 2017
-
Patent Title: Particles comprising single stranded rna and double stranded rna for immunomodulation May. 02, 2017
-
Patent Title: Identification of surface-associated antigens for tumor diagnosis and therapy Jan. 03, 2017
-
Patent Title: Use of flt3 ligand for enhancing immune responses in rna immunization Nov. 08, 2016
-
Patent Title: Modification of rna, producing an increased transcript stability and translation efficiency Oct. 25, 2016
-
Patent Title: Homo- and heterodimeric smac mimetic compounds as apoptosis inducers Apr. 26, 2016
-
Patent Title: Vaccine composition comprising 5′-cap modified rna Mar. 29, 2016
-
Patent Title: Identification of tumor-associated cell surface antigens for diagnosis and therapy Feb. 23, 2016
-
Patent Title: Identification of surface-associated antigens for tumor diagnosis and therapy Nov. 24, 2015
-
Patent Title: Identification of tumor-associated markers for diagnosing or monitoring ovarian cancer Nov. 03, 2015
-
Patent Title: Identification of tumor-associated cell surface antigens for diagnosis and therapy Sep. 22, 2015
-
Patent Title: Polynucleotides encoding an intracellular segment of cd40 and a constant region of an immunoglobulin heavy chain Sep. 22, 2015
-
Patent Title: Site-specific antibody-mediated activation of proapoptotic cytokines: amaizee (antibody-mediated apoptosis inducing cytokines) Mar. 17, 2015
-
Patent Title: Antigen-specific clonal expansion of b cells Feb. 03, 2015
-
Patent Title: Tumor vaccination involving a humoral immune response against self-proteins Sep. 23, 2014
-
Patent Title: Recombinant vaccines and use thereof Jan. 28, 2014
-
Patent Title: Use of microproteins as tryptase inhibitors Oct. 02, 2012
-
Patent Title: Dimeric or multimeric microproteins Sep. 04, 2012
-
Patent Title: Recombinant vaccines and use thereof May. 15, 2012
Federal grants, loans, and purchases
Followers on BNTX's company Twitter account
Number of mentions of BNTX in WallStreetBets Daily Discussion
Recent insights relating to BNTX
Recent picks made for BNTX stock on CNBC
ETFs with the largest estimated holdings in BNTX
Flights by private jets registered to BNTX